Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 139 for “"basal-like"”.

  1. Hippo pathway Inactivation drives basal-like mammary tumorigenesis

    Basal-like breast cancers make up an aggressive subtype of breast cancer with diverse intratumor cell heterogeneity and poor clinical outcomes. These cancers are predominantly triple-negative cancers such that they lack expression of estrogen receptor, progesterone receptor, and human epidermal …

    bu Repository record for Hippo pathway Inactivation drives basal-like mammary tumorigenesis (opens in a new tab)

  2. Clinical utility of biomarkers for basal-like breast cancer

    … growth factor receptor-2 (Her2)-Enriched and basal-like has remarkably advanced breast cancer diagnosis, treatment, and outcome. However, comparatively few advancements have been made in identifying biomarkers that can tailor treatments for the aggressive basal-like subtype. This group is …

    ubc Repository record for Clinical utility of biomarkers for basal-like breast cancer (opens in a new tab) Download PDF for Clinical utility of biomarkers for basal-like breast cancer (opens in a new tab)

  3. Revealing Putative Drug Targets for Basal-Like Breast Cancer

    … has limited treatment options for patients with Basal-like breast cancer to non-selective cytotoxic and cytostatic drugs. This research aimed to reveal putative drug targets for Basal-like breast cancer. The advances of sequencing technologies and computational methods have benefited drug target …

    whiterose Download PDF for Revealing Putative Drug Targets for Basal-Like Breast Cancer (opens in a new tab)

  4. IGF2 Promotes Activation of Estrogen Receptors in Basal-like Breast Cancer Cells

    … breast cancer (BC) progression. Basal-like BC (BLBC) is a sub-group of estrogen-independent tumors that have a very aggressive clinical behavior and are resistant to hormone-based therapy resulting in reduced disease-free survival period and increasing the mortality of breast …

    loma-linda Repository record for IGF2 Promotes Activation of Estrogen Receptors in Basal-like Breast Cancer Cells (opens in a new tab)

  5. Cytotoxic Activity of Sphingosine-1-Phosphate against Human Triple-negative/ Basal-like Breast Cancer

    … (TNBC), does not respond to hormonal therapy. Basal-like breast cancer (BLBC) has shorter overall survival rate among other subtypes. Tumors sharing both TNBC and BLBC are considered less responsive to currently available treatment. Chemoresistance to treatment has been a challenge in cancer …

    sask Repository record for Cytotoxic Activity of Sphingosine-1-Phosphate against Human Triple-negative/ Basal-like Breast Cancer (opens in a new tab)

  6. Pre-clinical trials with precision-medicine based therapeutics in basal-like patient-derived xenografts

    … progesterone receptor, or are positive for HER2. Basal-like breast cancer tends to not have these biomarkers, which necessitates their treatment to be traditional, untargeted therapeutics which are less effective and tend to have harsh adverse effect profiles – this is an important unmet need. …

    vcu Repository record for Pre-clinical trials with precision-medicine based therapeutics in basal-like patient-derived xenografts (opens in a new tab)

  7. The Role of MicroRNAs in the Fibroblasts of Triple Negative and Basal-like Breast Cancer

    … influence on tumour behaviour and prognosis. The basal-like subtype, which is typically – but not always – triple negative for receptor expression status limiting treatment options, represents one of the main subtypes with relatively poor prognosis. Breast cancer is a disease that comprises not …

    whiterose Download PDF for The Role of MicroRNAs in the Fibroblasts of Triple Negative and Basal-like Breast Cancer (opens in a new tab)

  8. Investigating the Mechanisms of Resistance to Dual PI3K/MTOR Inhibitor in PIK3CA Mutant Basal Like Bladder Cancer

    … status as well as tumor subtype (luminal-like or basal-like) play cooperative role in driving treatment response, where PIK3CA E542K mutation in basal-like tumors is associated with resistance to PI3K inhibition. Resistance is driven by feedback activation of alternative feedback signaling …

    iupui Repository record for Investigating the Mechanisms of Resistance to Dual PI3K/MTOR Inhibitor in PIK3CA Mutant Basal Like Bladder Cancer (opens in a new tab)

  9. Inhibitor of Differentiation 4: a new player in the DNA damage repair pathway in basal-like breast cancer

    Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Poor survival is compounded by a lack of targeted treatments. Detailed understanding of the molecular …

    unsw Repository record for Inhibitor of Differentiation 4: a new player in the DNA damage repair pathway in basal-like breast cancer (opens in a new tab)

  10. KPT-330 synergizes with everolimus to reduce mTORC1-overactive basal-like triple-negative breast cancer brain metastasis burden

    … 20% of all breast cancer diagnoses. Basal-like TNBC is notably difficult to treat due to the lack of actionable drug targets such as estrogen and progesterone receptors, as well as HER2. Due to the deficiency in TNBC-targeting drugs that are able to cross the blood-brain barrier (BBB) …

    vcu Repository record for KPT-330 synergizes with everolimus to reduce mTORC1-overactive basal-like triple-negative breast cancer brain metastasis burden (opens in a new tab)

  11. Vestigial-Like 1 Is A Shared Targetable Cancer-Placenta Antigen Expressed By Pancreatic and Basal-Like Breast Cancers

    … from co-transcriptional activator Vestigial-like 1 (VGLL1), a novel putative TAA demonstrating overexpression in multiple tumor types and low or absent transcript expression in normal tissues with the exception of placenta. VGLL1-specific CTL isolated and expanded from the blood of a male …

    uthsc Repository record for Vestigial-Like 1 Is A Shared Targetable Cancer-Placenta Antigen Expressed By Pancreatic and Basal-Like Breast Cancers (opens in a new tab)

  12. The chemokine CCL2/CCR2 signaling mediates cancer associated fibroblasts-cancer cells interaction and promotes basal-like breast cancer progression

    … diagnosed in women in the United States. The basal-like breast cancer subtype represents about 12% of breast cancer and has the worst outcome in patients due to lack of effective therapies. Tumor stroma plays an important role in cancer progression. Cancer associated fibroblasts (CAFs) are the …

    ku Repository record for The chemokine CCL2/CCR2 signaling mediates cancer associated fibroblasts-cancer cells interaction and promotes basal-like breast cancer progression (opens in a new tab)

  13. The covalent JNK inhibitor, JNK-in-8, synergizes with lapatinib to cause cell death in basal-like breast cancer cell lines

    Basal-like and Claudin-low breast cancers have the worst prognosis and represent 15-20% of breast cancers diagnosed each year. Endocrine and molecularly targeted therapies are ineffective for these tumors due to lack of Estrogen Receptor (ER) or Human Epidermal Growth Factor Receptor 2 (HER2) …

    texas Repository record for The covalent JNK inhibitor, JNK-in-8, synergizes with lapatinib to cause cell death in basal-like breast cancer cell lines (opens in a new tab)

  14. Investigation Of Death Receptor-5 Mediated Apoptosis And Inhibition Of Wnt/ß-Catenin Signaling In Basal-Like Breast Cancer Stem Cells

    Basal-like breast cancers (BLBC) display aggressive clinical behavior attributed to the presence of cancer stem cells (CSCs). TRA-8, a monoclonal antibody that binds specifically to TRAIL death receptor 5, preferentially induces apoptosis in BLBC subtype cells; however it is unknown if TRA-8 is …

    uab Repository record for Investigation Of Death Receptor-5 Mediated Apoptosis And Inhibition Of Wnt/ß-Catenin Signaling In Basal-Like Breast Cancer Stem Cells (opens in a new tab)

  15. Clinical performance of diagnostic, prognostic and predictive immunohistochemical biomarkers for hormone receptor-negative breast cancer

    … particularly aggressive subtype referred to as “basal-like”, which comprises ~15% of all cases, afflicts younger women and is refractory to endocrine and anti-HER2 therapies. Immunohistochemical surrogate definitions for basal-like breast cancer, such as the ER/PR/HER2 triple negative phenotype …

    ubc Repository record for Clinical performance of diagnostic, prognostic and predictive immunohistochemical biomarkers for hormone receptor-negative breast cancer (opens in a new tab) Download PDF for Clinical performance of diagnostic, prognostic and predictive immunohistochemical biomarkers for hormone receptor-negative breast cancer (opens in a new tab)

Page 1 of 7